NYSE$MBI
MBIA Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Grupo Fleury reported strong revenue growth and improved profitability in the fourth quarter of 2024, driven by strategic acquisitions and operational efficiencies.
Grupo Fleury achieved a gross revenue of R$ 2.0 billion in 4Q24, an 8.7% increase over 4Q23, with EBITDA reaching R$ 405.5 million (22.0% margin) and Net Income of R$ 84.0 million. The company demonstrated consistent performance across its segments, with significant growth in mobile services and B2B diagnostic medicine, while maintaining a solid financial structure with reduced leverage.
- Gross Revenue reached R$ 1,994.3 million in 4Q24, an 8.7% increase compared to 4Q23.
- EBITDA for 4Q24 was R$ 405.5 million, with a margin of 22.0%, showing a 7.9% growth over 4Q23.
- Net Income for 4Q24 stood at R$ 84.0 million, a 3.3% increase from 4Q23, with a net margin of 4.6%.
- The company's leverage decreased to 1.0x Net Debt/EBITDA by the end of 2024, down from 1.2x in 2023.
Headline financials
Revenue & EPS history
MBIA · Revenue · Quarterly
$1.99B
Forward guidance
The company did not provide specific forward-looking financial guidance for 2025. However, it emphasized its commitment to disciplined capital allocation, continued evaluation of strategic opportunities, and strengthening its position as a leading healthcare provider in Brazil through integrated and sustainable solutions.
Tailwinds
- Continued focus on operational efficiency and financial strength.
- Strategic acquisitions like Grupo São Lucas and Confiance Diagnostic Medicine are expected to enhance geographic reach and operational synergies.
- Ongoing innovation in integrated centers and digital solutions to improve customer experience and productivity.
- Strong financial structure with lower debt levels and effective financial debt management.
- Commitment to expanding its portfolio of services and market presence.
Headwinds
- No specific negative forward guidance was provided in the report.
- The report does not detail potential macroeconomic challenges that could impact future performance.
- No explicit mention of expected changes in regulatory environment or healthcare policies.
- No specific targets or ranges for future revenue, EBITDA, or net income were disclosed.
- The report does not address potential competitive pressures or market saturation in key segments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.3%
Avg return
Earnings day
-0.9%
Avg return
5 days after
+0.9%
Avg return
30 days after
45%
30 / 66 earnings
Positive
+32.5%
Q3 2017
Best reaction
-20.6%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +3.3% | -3.2% | -8.6% | |
| Q3 2025 | +9.0% | +11.4% | +8.6% | |
| Q1 2025 | -1.3% | -8.8% | -6.7% | |
| Q4 2024 | -13.5% | -21.7% | -28.6% | |
| Q3 2024 | +4.2% | +11.8% | +56.4% | |
| Q1 2024 | -9.3% | -10.6% | -20.4% | |
| Q4 2023 | -4.4% | -5.3% | -1.0% | |
| Q3 2023 | -6.5% | -5.7% | +4.2% | |
| Q2 2023 | -1.7% | +1.4% | -6.0% | |
| Q1 2023 | -17.5% | -17.5% | -9.7% | |
| Q4 2022 | -10.0% | -8.4% | -34.1% | |
| Q3 2022 | +6.3% | +7.8% | +15.1% | |
| Q2 2022 | -16.1% | -5.8% | -7.6% | |
| Q1 2022 | -9.6% | -7.1% | +10.3% | |
| Q4 2021 | -20.6% | -9.3% | -0.1% | |
| Q3 2021 | -0.7% | +1.0% | -26.1% | |
| Q2 2021 | -8.4% | -8.1% | -15.8% | |
| Q1 2021 | -12.9% | -9.5% | +2.6% | |
| Q4 2020 | -1.6% | +5.2% | +31.8% | |
| Q3 2020 | +10.4% | +4.6% | +27.0% | |
| Q2 2020 | -0.6% | +5.5% | +2.3% | |
| Q1 2020 | -13.3% | -17.4% | -3.6% | |
| Q4 2019 | -2.7% | -2.3% | -10.2% | |
| Q3 2019 | +10.5% | +7.4% | -2.4% | |
| Q2 2019 | -4.6% | +0.0% | +1.9% | |
| Q1 2019 | +5.5% | -4.7% | -5.6% | |
| Q4 2018 | +6.6% | +7.0% | -4.3% | |
| Q3 2018 | -3.2% | -9.4% | -15.2% | |
| Q2 2018 | +8.3% | +3.3% | -0.2% | |
| Q1 2018 | +2.3% | +3.5% | +12.4% | |
| Q4 2017 | +1.1% | +7.4% | +15.9% | |
| Q3 2017 | +32.5% | +32.6% | +20.6% | |
| Q2 2017 | +3.0% | +3.7% | +0.0% | |
| Q1 2017 | +10.8% | +3.3% | +10.0% | |
| Q4 2016 | -3.5% | -7.2% | -17.9% | |
| Q3 2016 | +7.9% | +17.6% | +45.1% | |
| Q2 2016 | -1.1% | -4.7% | -6.4% | |
| Q1 2016 | +0.7% | — | — | |
| Q4 2015 | +9.5% | — | — | |
| Q3 2015 | +2.5% | — | — | |
| Q2 2015 | -0.5% | — | — | |
| Q1 2015 | +4.0% | — | — | |
| Q4 2014 | +3.1% | — | — | |
| Q3 2014 | +1.9% | — | — | |
| Q2 2014 | +1.8% | — | — | |
| Q1 2014 | +2.1% | — | — | |
| Q4 2013 | +9.5% | — | — | |
| Q3 2013 | +5.4% | — | — | |
| Q2 2013 | -5.6% | — | — | |
| Q1 2013 | -0.4% | — | — | |
| Q4 2012 | -2.3% | — | — | |
| Q3 2012 | -12.4% | — | — | |
| Q4 2011 | +11.2% | — | — | |
| Q2 2012 | +11.2% | — | — | |
| Q1 2012 | +3.0% | — | — | |
| Q3 2011 | -5.4% | — | — | |
| Q2 2011 | -0.3% | — | — | |
| Q1 2010 | -3.8% | — | — | |
| Q1 2011 | -1.8% | — | — | |
| Q4 2008 | -6.2% | — | — | |
| Q4 2009 | -6.2% | — | — | |
| Q4 2010 | -6.2% | — | — | |
| Q3 2010 | -4.9% | — | — | |
| Q3 2009 | -4.9% | — | — | |
| Q2 2010 | +8.2% | — | — | |
| Q2 2009 | +8.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro